Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932697 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
A Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 2
- Study locations
NCT01932697: Completed Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma, sponsored by Mayo Clinic.
NCT01932697 is a Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma that has completed, run by Mayo Clinic. The registered enrollment target is 81 participants, below the 1,275-participant average among 22 other Human Papillomavirus Infection trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01932697, a Phase 2 study of Human Papillomavirus Infection and Stage I Oropharyngeal Squamous Cell Carcinoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy with docetaxel my kill more tumor cells.
Primary Outcome
The 2-year loco-regional tumor control (LRC) rate (percentage) is defined as the percentage of patients with no local/regional recurrence or death 2 years after study registration.
Conditions Studied
Interventions
- DRUG Docetaxel
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- RADIATION Intensity-Modulated Radiation Therapy
- RADIATION Hyperfractionation
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-09-04 |
| Est. Completion | 2021-12-28 |
| Phase | Phase 2 |
What the finished NCT01932697 record still lists
NCT01932697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,275-participant average among 22 other Human Papillomavirus Infection trials with a reported enrollment target (94% lower).
The record links to 6 conditions, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT01932697 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01932697 about?
NCT01932697 is a clinical study titled "Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer". This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop th...
What is the current status of trial NCT01932697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2013-09-04. Estimated completion is 2021-12-28.
What conditions does trial NCT01932697 study?
This clinical trial studies the following conditions: Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT01932697?
The interventions under investigation include: Docetaxel (DRUG), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Intensity-Modulated Radiation Therapy (RADIATION), Hyperfractionation (RADIATION).
Who is sponsoring clinical trial NCT01932697?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01932697 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01932697's enrollment target sits among peer trials
81 20th of 22 higher than 3 of 22 other Human Papillomavirus Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papillomavirus Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
COMPLETED · Phase 2
-
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
COMPLETED · Phase 2
-
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI